An investigational site is the facility or the specific location where the study-related activities of a clinical trial are conducted. Depending on the protocol, these include informed consent, examinations, dispensing or administration of the investigational medicinal product, safety monitoring, and the collection and documentation of study data. An investigational site can be, for example, a hospital, a practice, a medical care center, or a specialized research facility.<\/p>\n
In a multicenter clinical trial, each investigational site forms an operational hub between trial participants, investigator, study team, sponsor and, if applicable, commissioned CRO. The site implements the approved protocol locally and must protect the rights, safety, dignity and well-being of the participants. At the same time, the essential source data from which the analysis and assessment of the trial are derived are generated there.<\/p>\n
The responsibility for medical care and conduct at the site lies with the investigator. He may delegate tasks to qualified team members but remains responsible for the appropriate performance of the delegated activities. In contrast, the sponsor is responsible for the planning, initiation, organization and financing of the clinical trial. The investigational site is therefore neither to be equated with the investigator as a person nor with the sponsor: it is the institutional and spatial unit suitable for the conduct.<\/p>\n
An investigational site must be suitable for the planned trial. This includes sufficiently qualified personnel, appropriate premises and equipment, secure processes for investigational medicinal products, as well as the ability to identify and medically care for participants according to the inclusion and exclusion criteria. Suitability is not measured solely by the professional experience of the investigator. Crucial are also available time, delegation structures, emergency routes, data protection, archiving and robust access to the intended patient population.<\/p>\n
Under Regulation (EU) No 536\/2014, the suitability of the investigator and the facilities are among the aspects reviewed for the national assessment. The application documents therefore contain site-specific information, such as on the investigator, the suitability of the facility, recruitment modalities, informed consent and financial agreements. During the conduct, the site must manage the investigational medicinal products traceably, keep relevant documents available and enable monitoring, audits as well as regulatory inspections.<\/p>\n
The pre-study visit is usually a preliminary suitability or selection visit. Based on the protocol, the sponsor or CRO assesses whether the potential investigational site can meet the medical, organizational and infrastructural requirements. Discussed are, for instance, expected recruitment, experience of the team, local standard procedures, laboratory and pharmacy routes, storage conditions and the availability of study rooms. The visit does not replace regulatory approval but creates a documented basis for site selection.<\/p>\n
The site initiation follows after selection and the necessary approvals prior to recruitment. It serves the joint, documented preparation of the site for the specific trial. The team is trained on the protocol, informed consent process, safety reporting, data flow, delegation, investigational medicinal product and communication channels. A site should only include participants when its prerequisites, documents and study-specific procedures are fully activated. These two steps are operational quality measures; their specific design depends on a risk-based approach according to the trial and site.<\/p>\n
The investigator is the responsible person for the conduct of the clinical trial at an investigational site. The investigational site, on the other hand, encompasses the location, the facility and the resources available there, where the trial takes place. Multiple investigators can work at one site; in this case, an investigator as Principal Investigator leads the team. The term therefore does not describe an individual qualification or role designation.<\/p>\n
The sponsor initiates, organizes and finances the clinical trial and bears the overall responsibility for quality management and safety monitoring. He may transfer tasks to a CRO without fully relinquishing his responsibility. The investigational site conducts the trial at the location and remains integrated into the overarching guidelines, contracts and monitoring processes. The clear separation prevents unclear responsibilities in case of protocol deviations, safety issues or data corrections.<\/p>\n
The selection and preparation of suitable investigational sites influences participant safety, recruitability and the reliability of the data. Unavailable resources, unclear delegation or insufficient training can lead to delays, protocol deviations or incomplete documentation. A risk-based view of the actual processes of the site is therefore more important than a purely formal checklist.<\/p>\n
Full-service CROs such as Mediconomics support with feasibility assessment, selection and qualification of investigational sites, with pre-study visits and site initiations as well as with contract and documentation processes. They also coordinate monitoring, training, communication channels and the follow-up of site-specific measures so that the conduct remains compliant with the protocol, GCP and regulatory requirements.<\/p>\n
Can an investigational site conduct multiple clinical trials at the same time?<\/strong><\/p>\n Yes, provided that personnel, rooms, equipment and time are sufficient for each individual trial. Suitability must be assessed on a study-specific basis, because protocols place different demands on the patient population, procedures and safety monitoring.<\/p>\n Is an investigational site always a hospital?<\/strong><\/p>\n No. Medical practices, medical care centers or specialized research facilities can also be investigational sites, provided they are suitable for the specific trial and guarantee the necessary medical care.<\/p>\n What distinguishes a pre-study visit from a site initiation?<\/strong><\/p>\n The pre-study visit assesses the suitability of a potential site prior to selection. The site initiation prepares a selected and approved site for the practical conduct of the trial prior to the first inclusion.<\/p>\n An investigational site is the facility or the specific location where the study-related activities of a clinical trial are conducted. Depending on the protocol, these include informed consent, examinations, dispensing or administration of the investigational medicinal product, safety monitoring, and the collection and documentation of study data. An investigational site can be, for example, a […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6666","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6666\/revisions"}],"predecessor-version":[{"id":7496,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6666\/revisions\/7496"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6666"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n